NGNE · Neurogene Inc. — research history
Complete research history. Every dossier, draft, kill, publish, and lesson the system has produced on NGNE. Public so users can audit, AI can re-reference. Live price refreshes every 60s.
About NGNE · Neurogene Inc.
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company was founded in 2018 and is headquartered in New York, New York.
Live Quote
BUY (score +7) · 12-1 mom 60.5% · RSI 58.7 · above_both · -10.2% from high
Targets blend Wall Street consensus (7 analysts: low $46.00 / mean $80.00 / high $180.00) with chart-derived floors and ceilings.
1-Year Chart · RSI · MACD
Research Timeline
Newest first. Each entry shows what stage produced it, the verdict/decision, and the reasoning.
Neurogene is a pre-revenue clinical-stage biotech focused on gene therapy for rare neurological diseases with its lead candidate NGN-401 in a registrational trial for Rett syndrome. The investigation triggered on a Form 4 cluster, but upon examination all three recent filings were SELLING transactions — Christine Mikail Cvijic's May 6 sales (9,600 shares via pre-set 10b5-1 plan) and Christina Shafer's option grant are not open-market purchases. The broader insider history shows mandatory tax-withholding sells on RSU vesting dates across multiple executives including CEO Rachel McMinn and CSO Stuart Cobb — none representing discretionary conviction buys. Dosing in the Embolden registrational trial was completed June 8, 2026, which is a genuine catalyst ahead of an August 11 earnings report. However, with no revenue, cash burn of ~$31M per quarter, analyst target at $80 vs. current price of $29.35 — this is not mispriced; the market appears correctly discounting binary biotech risk in an illiquid micro-cap with elevated IV (110-114%) and limited options liquidity.